| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Internal Medicine Department, Divisions of Nuclear Medicine and Hematology/Oncology, Radiation Oncology Department and Radiology Department, The University of Michigan Medical Center, Ann Arbor, Michigan
Correspondence: For correspondence and reprints contact: Kenneth F. Koral, PhD, 3480 Kresge III, University of Michigan Medical Center, 204 Zina Pitcher Place, Ann Arbor, MI 48109-0552.
ABSTRACT
A method for performing 131I quantitative SPECT imaging is described which uses the superimposition of markers placed on the skin to accomplish fusion of computed tomography (CT) and SPECT image sets. Methods: To calculate mean absorbed dose after administration of one of two 131I-labeled monoclonal antibodies (Mabs), the shape of the time-activity curve is measured by daily diagnostic conjugate views, the y-axis of that curve is normalized by a quantitative SPECT measurement (usually intra-therapy), and the tumor mass is deduced from a concurrent CT volume measurement. The method is applied to six B-cell non-Hodgkin's lymphoma patients. Results: For four tumors in three patients treated with the MB1 Mab, a correlation appears to be present between resulting mean absorbed dose and disease response. Including all dosimetric estimates for both antibodies, the range for the specific absorbed dose is within that found by others in treating B-cell lymphoma patients. Excluding a retreated anti-B1 patient, the tumor-specific absorbed dose during anti-B1 therapy is from 1.4 to 1.7 mGy/MBq. For the one anti-B1 patient, where quantitative SPECT and conjugate-view imaging was carried out back to back, the quantitative SPECT-measured activity was somewhat less for the spleen and much less for the tumor than that from conjugate views. Conclusion: The quantitative SPECT plus conjugate views method may be of general utility for macro-dosimetry of 131I therapies.
Key Words: radioimmunotherapy • SPECT • conjugate views • lymphoma • iodine-131
This article has been cited by other articles:
|
|
 |
|
  H. Zaidi and B. Hasegawa Determination of the Attenuation Map in Emission Tomography J. Nucl. Med., February 1, 2003; 44(2): 291 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. O. Dillman Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma J. Clin. Oncol., August 15, 2002; 20(16): 3545 - 3557. [Full Text] [PDF]
|
|
|
|
|
|
K. K. Matthay, C. Panina, J. Huberty, D. Price, D. V. Glidden, H. R. Tang, R. A. Hawkins, J. Veatch, and B. Hasegawa Correlation of Tumor and Whole-Body Dosimetry with Tumor Response and Toxicity in Refractory Neuroblastoma Treated with 131I-MIBG J. Nucl. Med., November 1, 2001; 42(11): 1713 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Tang, A. J. Da Silva, K. K. Matthay, D. C. Price, J. P. Huberty, R. A. Hawkins, and B. H. Hasegawa Neuroblastoma Imaging Using a Combined CT Scanner-Scintillation Camera and 131I-MIBG J. Nucl. Med., February 1, 2001; 42(2): 237 - 247. [Abstract] [Full Text]
|
|
|
|
|
|
Y. K. Dewaraja, M. Ljungberg, and K. F. Koral Accuracy of 131I Tumor Quantification in Radioimmunotherapy Using SPECT Imaging with an Ultra-High-Energy Collimator: Monte Carlo Study J. Nucl. Med., October 1, 2000; 41(10): 1760 - 1767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Rotman-Pikielny, J. C. Reynolds, W. C. Barker, P. M. Yen, M. C. Skarulis, and N. J. Sarlis Recombinant Human Thyrotropin for the Diagnosis and Treatment of a Highly Functional Metastatic Struma Ovarii J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 237 - 244. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
